Terms: = Prostate cancer AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK AND Treatment
475 results:
1. Knockdown of growth differentiation factor-15 restrains prostate cancer through regulating MAPK/erk signaling pathway.
Yang M; Guo M; Su C; Hao W; Xu Z
Cell Mol Biol (Noisy-le-grand); 2024 Mar; 70(3):162-167. PubMed ID: 38650142
[TBL] [Abstract] [Full Text] [Related]
2. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract] [Full Text] [Related]
3. Leptin promotes proliferation of human undifferentiated spermatogonia by activating the PI3K/AKT/mTOR pathway.
Xin S; Xiaoxuan L; Yixuan Z; Zhikang C
Am J Reprod Immunol; 2024 Jan; 91(1):e13811. PubMed ID: 38282611
[TBL] [Abstract] [Full Text] [Related]
4.
Giordano F; Comità S; Venneri G; Rago V; Naimo GD; De Amicis F; De Bartolo A; Tundis R; Mauro L; Panno ML
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003541
[TBL] [Abstract] [Full Text] [Related]
5. Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR.
Kim S; Park JM; Park S; Jung E; Ko D; Park M; Seo J; Nam KD; Kang YK; Lee K; Farrand L; Kim YJ; Kim JY; Seo JH
J Exp Clin Cancer Res; 2023 Nov; 42(1):292. PubMed ID: 37924112
[TBL] [Abstract] [Full Text] [Related]
6. Total flavonoids of Litchi chinensis Sonn. seed inhibit prostate cancer growth in bone by regulating the bone microenvironment via inactivation of the HGFR/NF-κB signaling pathway.
Zhang W; Chen T; Yang P; Li X; Zhu D; Su Z; Yang X; Jin R; Lan T; Guo H
J Ethnopharmacol; 2024 Jan; 319(Pt 3):117327. PubMed ID: 37871755
[TBL] [Abstract] [Full Text] [Related]
7. prostate cancer Stem Cells: Biology and treatment Implications.
Koukourakis IM; Platoni K; Kouloulias V; Arelaki S; Zygogianni A
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834336
[TBL] [Abstract] [Full Text] [Related]
8. Polyphyllin I induces ferroptosis in castration-resistant prostate cancer cells through the erk/DNMT1/ACSL4 axis.
Zou P; Chen Z; He Q; Zhuo Y
Prostate; 2024 Jan; 84(1):64-73. PubMed ID: 37750290
[TBL] [Abstract] [Full Text] [Related]
9. A novel isoxazole compound CM2-II-173 inhibits the invasive phenotype of triple-negative breast cancer cells.
Kim ES; Kim S; Moon A
Oncol Res; 2023; 31(6):867-875. PubMed ID: 37744269
[TBL] [Abstract] [Full Text] [Related]
10. RNA Interference against ATP as a Gene Therapy Approach for prostate cancer.
Chen S; Ma J; Xiao Y; Zhou D; He P; Chen Y; Zheng X; Lin H; Qiu F; Yuan Y; Zhong J; Li X; Pan X; Fang Z; Wang C
Mol Pharm; 2023 Oct; 20(10):5214-5225. PubMed ID: 37733628
[TBL] [Abstract] [Full Text] [Related]
11. TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer.
Wang F; Liu S; Liu F; Xu T; Ma J; Liang J; Wang J; Liu D; Yang F; Li J; Xing N
Cancer Lett; 2023 Aug; 568():216300. PubMed ID: 37414394
[TBL] [Abstract] [Full Text] [Related]
12. Holothurin A Inhibits RUNX1-Enhanced EMT in Metastasis prostate cancer via the Akt/JNK and p38 MAPK Signaling Pathway.
Janta S; Pranweerapaiboon K; Vivithanaporn P; Plubrukarn A; Chairoungdua A; Prasertsuksri P; Apisawetakan S; Chaithirayanon K
Mar Drugs; 2023 Jun; 21(6):. PubMed ID: 37367670
[TBL] [Abstract] [Full Text] [Related]
13. Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer.
Wang H; Li N; Liu Q; Guo J; Pan Q; Cheng B; Xu J; Dong B; Yang G; Yang B; Wang X; Gu Y; Zhang G; Lian Y; Zhang W; Zhang M; Li T; Zang Y; Tan M; Li Q; Wang X; Yu Z; Jiang J; Huang H; Qin J
Cancer Cell; 2023 Jul; 41(7):1345-1362.e9. PubMed ID: 37352863
[TBL] [Abstract] [Full Text] [Related]
14. Androgen receptor knockdown enhances prostate cancer chemosensitivity by down-regulating FEN1 through the erk/ELK1 signalling pathway.
Xie W; Li S; Guo H; Zhang J; Tu M; Wang R; Lin B; Wu Y; Wang X
Cancer Med; 2023 Jul; 12(14):15317-15336. PubMed ID: 37326412
[TBL] [Abstract] [Full Text] [Related]
15. Pretreatment of prostate cancer cells with salinomycin and Wnt inhibitor increases the efficacy of cabazitaxel by inducing apoptosis and decreasing cancer stem cells.
Serttas R; Erdogan S
Med Oncol; 2023 Jun; 40(7):194. PubMed ID: 37264204
[TBL] [Abstract] [Full Text] [Related]
16. The CCL2-CCR2 Axis Contributes to Migration of Cabazitaxel-resistant prostate cancer Cells.
Natsagdorj A; Izumi K; Hiratsuka K; Naito R; Kadomoto S; Iwamoto H; Yaegashi H; Shigehara K; Nakata H; Mizokami A
Anticancer Res; 2023 Jun; 43(6):2561-2569. PubMed ID: 37247914
[TBL] [Abstract] [Full Text] [Related]
17. SALL4 correlates with proliferation, metastasis, and poor prognosis in prostate cancer by affecting MAPK pathway.
Zhou J; Peng S; Fan H; Li J; Li Z; Wang G; Zeng L; Guo Z; Lai Y; Huang H
Cancer Med; 2023 Jun; 12(12):13471-13485. PubMed ID: 37119046
[TBL] [Abstract] [Full Text] [Related]
18. MKK4 Inhibitors-Recent Development Status and Therapeutic Potential.
Katzengruber L; Sander P; Laufer S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108658
[TBL] [Abstract] [Full Text] [Related]
19. Post-transcriptional modification of m
Li Y; Zhu S; Chen Y; Ma Q; Kan D; Yu W; Zhang B; Chen X; Wei W; Shao Y; Wang K; Zhang M; Deng S; Niu Y; Shang Z
Cell Death Dis; 2023 Apr; 14(4):289. PubMed ID: 37095108
[TBL] [Abstract] [Full Text] [Related]
20. The endocannabinoid system, a new gatekeeper in the pharmacology of human hepatocellular carcinoma.
Ebrahimi N; Far NP; Fakhr SS; Faghihkhorasani F; Miraghel SA; Chaleshtori SR; Rezaei-Tazangi F; Beiranvand S; Baziyar P; Manavi MS; Zarrabi A; Nabavi N; Ren J; Aref AR
Environ Res; 2023 Jul; 228():115914. PubMed ID: 37062475
[TBL] [Abstract] [Full Text] [Related]
[Next]
